View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCheilbio 配当と自社株買い配当金 基準チェック /06Cheilbio配当金を支払った記録がありません。主要情報n/a配当利回り-5.1%バイバック利回り総株主利回り-5.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.すべての更新を表示Recent updatesBoard Change • Feb 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 14Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 131, sandan-ro 83beon-gil, danwon-gu, gyeonggi-do, ansan South Koreaお知らせ • Sep 26Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others.Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others on September 25, 2024. Agreement is expected to be signed on September 27, 2024, and expected completion of the transaction is December 1, 2024.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,300, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩2,450, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 5.4% over the past three years.分析記事 • Mar 15A Look At The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. ( KOSDAQ:052670 ) by taking the...Is New 90 Day High Low • Feb 20New 90-day low: ₩6,700The company is down 19% from its price of ₩8,270 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: ₩7,250The company is down 7.0% from its price of ₩7,770 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.分析記事 • Jan 21Can You Imagine How Cheilbio's (KOSDAQ:052670) Shareholders Feel About The 83% Share Price Increase?By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...Is New 90 Day High Low • Dec 28New 90-day low: ₩7,410The company is down 3.0% from its price of ₩7,650 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.分析記事 • Nov 29Estimating The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. (KOSDAQ:052670) by taking the...Is New 90 Day High Low • Sep 24New 90-day low: ₩7,070The company is down 10.0% from its price of ₩7,880 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.決済の安定と成長配当データの取得安定した配当: A052670の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A052670の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Cheilbio 配当利回り対市場A052670 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A052670)n/a市場下位25% (KR)1.3%市場トップ25% (KR)4.2%業界平均 (Pharmaceuticals)1.0%アナリスト予想 (A052670) (最長3年)n/a注目すべき配当: A052670は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A052670は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A052670の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A052670が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/22 23:47終値2026/02/20 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cheilbio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Board Change • Feb 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 14Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 131, sandan-ro 83beon-gil, danwon-gu, gyeonggi-do, ansan South Korea
お知らせ • Sep 26Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others.Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others on September 25, 2024. Agreement is expected to be signed on September 27, 2024, and expected completion of the transaction is December 1, 2024.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,300, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩2,450, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 5.4% over the past three years.
分析記事 • Mar 15A Look At The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. ( KOSDAQ:052670 ) by taking the...
Is New 90 Day High Low • Feb 20New 90-day low: ₩6,700The company is down 19% from its price of ₩8,270 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: ₩7,250The company is down 7.0% from its price of ₩7,770 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
分析記事 • Jan 21Can You Imagine How Cheilbio's (KOSDAQ:052670) Shareholders Feel About The 83% Share Price Increase?By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Is New 90 Day High Low • Dec 28New 90-day low: ₩7,410The company is down 3.0% from its price of ₩7,650 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
分析記事 • Nov 29Estimating The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. (KOSDAQ:052670) by taking the...
Is New 90 Day High Low • Sep 24New 90-day low: ₩7,070The company is down 10.0% from its price of ₩7,880 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.